<DOC>
	<DOCNO>NCT01555489</DOCNO>
	<brief_summary>The investigator recently complete phase I study intravenous ascorbic acid ( IV AA ) plus standard chemotherapy ( gemcitabine erlotinib ) patient metastatic pancreatic cancer . The investigator determine target ceiling dosage 100 gram ascorbic acid safe give chemotherapy . This Phase II trial initial test efficacy 100 gram dose ascorbic acid , give standard chemotherapy . This open label study recruit 35 subject metastatic pancreatic cancer receive ascorbic acid combine gemcitabine erlotinib front-line treatment . The phase I data suggests ascorbic acid give combination gemcitabine erlotinib may result tumor response , goal study well evaluate response confirm initial safety data</brief_summary>
	<brief_title>Assessing Efficacy Safety IV Vitamin C Combination With Standard Chemotherapy Pancreatic Ca</brief_title>
	<detailed_description>Intravenous high dose ascorbic acid widely use alternative cancer treatment . Patients receive standard care gemcitabine/erlotinib treatment metastatic pancreatic adenocarcinoma . They closely monitor disease response/ progression . If vitamin C beneficial effect tumour cell , patient may experience regression tumor tumor marker . Additional benefit include scan charge patient . This study require several day treatment per week treatment give two different location . The intravenous vitamin C treatment give 3 time per week , give every week initial cycle 15 week .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>Males female age ≥ 18 Histologically cytologically confirm pancreatic adenocarcinoma metastatic disease measurable CT , MRI , PET Subjects unresectable pancreatic cancer surgery ( exploratory laparotomy , biliary , gastrointestinal bypass ) eligible , subject fully recover surgery ≥ 14 day pass since operation . Patients history pancreatoduodenectomy eligible provide radiographically documented disease recurrence . ECOG performance status 02 Laboratory value would prevent patient receive chemotherapy determine PI study oncologist G6PD status ≥ low limit normal Serum creatinine ≤ 2.0 mg/dL Islet cell acinar cell carcinoma cystadenocarcinoma History know presence central nervous system ( CNS ) metastases History another primary cancer , except : Curatively treat cervical carcinoma situ , Curatively resect nonmelanomatous skin cancer , Other primary solid tumor curatively treat know active disease present treatment administer ≥ 3 year prior enrollment Other concurrent anticancer chemotherapy Prior radiotherapy ≤ 14 day , subject recover radiotherapy Uncontrolled seizure disorder serious neurological disease Any comorbid disease would increase risk toxicity determine PI Only locally advance disease Prior treatment gemcitabine ( metastatic pancreatic cancer ) Subjects require chronic use immunosuppressive agent ( eg , methotrexate , cyclosporine , corticosteroid ) Recent infection require course systemic antiinfection complete ≤ 14 day prior enrollment ( exception make judgment PI oral treatment uncomplicated urinary tract infection ( [ UTI ] ) History medical psychiatric condition addictive disorder , laboratory abnormality , opinion PI , may increase risk associate study participation study drug administration may interfere conduct study interpretation study requirement Subject unwilling unable comply study requirement Subject pregnant breast feed Known positive test ( ) human immunodeficiency virus infection , hepatitis C virus , chronic active hepatitis B infection Documented history alcohol , cocaine intravenous drug abuse ≤ 6 month enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pancreatic Neoplasms</keyword>
	<keyword>Pancreatic Cancer cell</keyword>
	<keyword>Digestive System Neoplasms</keyword>
	<keyword>Neoplasms Site</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Endocrine Gland Neoplasms</keyword>
	<keyword>Digestive System Diseases</keyword>
	<keyword>Pancreatic Diseases</keyword>
	<keyword>Endocrine System Diseases</keyword>
	<keyword>Ascorbic Acid</keyword>
	<keyword>Gemcitabine Vitamins</keyword>
	<keyword>Vitamin C</keyword>
	<keyword>Antioxidants</keyword>
	<keyword>Molecular Mechanisms Pharmacological Action</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Protective Agents</keyword>
	<keyword>Physiological Effects Drugs</keyword>
	<keyword>Micronutrients</keyword>
	<keyword>Growth Substances</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>Integrative Medicine</keyword>
	<keyword>Alternative Medicine</keyword>
	<keyword>Complementary Medicine</keyword>
</DOC>